Alendronate Sodium supplier & exporter
Product Description
| API name | Alendronate Sodium |
| CAS Number | 121268-17-5 |
| Therapeutic Category | Antiosteoporotic |
| Route of Administration | Tablet |
| Regulatory Documents | USDMF, CEP, ASMF, CANADA DMF, TAIWAN DMF, DMF, JDMF, CEP, WC |
Trader & Wholesaler of Alendronate Sodium
Mechanism of Action:
Alendronic acid binds to bone hydroxyapatite. Bone resorption causes local acidification, releasing alendronic acid which is that taken into osteoclasts by fluid-phase endocytosis. Endocytic vesicles are acidified, releasing alendronic acid to the cytosol of osteoclasts where they induce apoptosis.
Drug Indications:
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget’s disease of bone.